Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients

A phase I study of a new cancer vaccine (KRM‐10), consisting of a mixture of 10 different short peptides, was conducted for patients with advanced gastrointestinal cancers. Primary or secondary endpoints included the dose‐limiting toxicity (DLT), or safety and immune responses, respectively. Peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasa, Satoru, Yamada, Yasuhide, Heike, Yuji, Shoji, Hirokazu, Honma, Yoshitaka, Komatsu, Nobukazu, Matsueda, Satoko, Yamada, Akira, Morita, Michi, Yamaguchi, Rin, Tanaka, Natsuki, Kawahara, Akihiko, Kage, Masayoshi, Shichijo, Shigeki, Sasada, Tetsuro, Itoh, Kyogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970826/
https://www.ncbi.nlm.nih.gov/pubmed/26920496
http://dx.doi.org/10.1111/cas.12919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970826/
https://www.ncbi.nlm.nih.gov/pubmed/26920496
http://dx.doi.org/10.1111/cas.12919

Ejemplares similares